Indication intelligence, analysis and sector perception

Aduro Biotech’s (ADRO) Pancreatic Study Misses the Mark

May 16, 2016 10:29am

P2 Eclipse trial fails to meet improvement in overall patient survival

Pre-market trading halted with ADRO DOWN more than 25%

Calling it an “unexpected outcome”, ADRO said its P2 Eclipse study in patients with pancreatic cancer patients who failed at least two prior therapies showed a divergence of data from the results of its P2a study.

Median overall survival (MOS) in the third-line and greater setting was 3.8 months for patients treated with the immunotherapy regimen of CRS-207 and GVAX Pancreas, 5.4 months for patients treated withCRS-207 alone and 4.6 months for patients administered chemotherapy.

The Bottom Line: ADRO’s findings are disappointing to say the least.

ADRO closed UP Friday $0.45 to $10.69 and is DOWN -$2.78 or -26% to $7.91 in Monday's morning session.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 22 min ago
RegMed Investors’ (RMi) pre-open: finding our way

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.